Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - In this podium presentation, Dr. Robert Blackwell presented complications with urologic relevance in seen in 888 patients undergoing radiation therapy (RT) for prostate cancer at a single institution between 1992 and 2013. Patients receiving RT as primary or salvage therapy were included. With a median follow up of 4 years, the study found that 5- and 10-year risk for gross or microscopic hematuria was 23% and 42%, occurring at a median of 36 months. Overall 15% of the cohort experienced gross hematuria. Smoking history was found, on multivariate analysis, to be associated with an increased risk of hematuria (HR 2.6, p=0.001). auaUrethral stricture 5- and 10-year risk was 7% and 12% respectively, occurring at a median of 38 months. The majority of strictures were seen in the bladder neck and bulbar urethra, and on multivariate analysis, combined RT (EBRT+brachytherapy, HR 3.8, p=0.006) and adjuvant RT (HR 3.1, p=0.02) were associated with a higher risk for developing a urethral stricture than EBRT alone. Obesity also was associated with higher risk for stricture (HR 2.5, p < 0.01). The 5- and 10-year risk for bladder cancer was 2% and 5%, occurring at a median of 57 months. Histology was urothelial in all cases, and of concern, 37% of the bladder cancers in the cohort were muscle-invasive or metastatic at presentation.

On multivariate analysis, each year increase in age at the time of RT was associated with a 10.5% increased risk of developing bladder cancer (p=0.03). Interestingly smoking was not associated with an increased risk of bladder cancer in this cohort on multivariate analysis. Dr. Blackwell noted that, strikingly, the incidence for each of these 3 sequelae continued to increase over time, and further, that the side effects for RT for prostate cancer treatment are likely underestimated and urged further study to better understand their long-term significance.

Presented by Robert Blackwell, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Loyola University Medical Center, Maywood, IL USA

Written by Timothy Ito, MD, medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting